Combined androgen deprivation with radiotherapy for prostate cancer: Does it make sense?

Mark Garzotto, A. D'Amico, N. Bruchovsky, G. Sufrin, Zietman, N. Stone, D. Grignon, F. Civantos, D. Bostwick, L. Klotz

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Currently, our understanding of the mechanism(s) of radiation-induced death of prostate cancer is limited. In-depth analysis of these processes would facilitate the design of more effective treatment strategies utilizing radiation therapy. An increasingly recognized form of radiation-induced death is postmitotic apoptosis. In this process, radiation damages the tumor cell's DNA. The cell then divides prior to completing DNA repair, an event that is lethal. In order to avoid this fate, the cancer cell may attempt to halt its cell-cycle machinery temporarily to repair its DNA prior to dividing. In the treatment of prostate cancer, radiation therapy currently is being evaluated in combination with androgen deprivation (AD). However, because AD can induce growth arrest, it may reduce the effectiveness of radiation through a reduction in postmitotic apoptosis. To study this effect, we examined the effect of AD on prostate cancer radiosensitivity as it is related to cell-cycle progression. Androgen-sensitive prostate cancer cells demonstrated increased resistance to radiation when deprived of androgenic stimuli. Thus, paradoxically, AD may reduce the radiosensitivity of prostate cancer by means of cell-cycle delay, which results in a reduction in postmitotic apoptosis.

Original languageEnglish (US)
Pages (from-to)209-213+215
JournalMolecular Urology
Volume4
Issue number3
StatePublished - 2000
Externally publishedYes

Fingerprint

Androgens
Prostatic Neoplasms
Radiotherapy
Radiation
Cell Cycle
Radiation Tolerance
Apoptosis
DNA Repair
Neoplasms
DNA
Therapeutics
Growth

ASJC Scopus subject areas

  • Urology

Cite this

Garzotto, M., D'Amico, A., Bruchovsky, N., Sufrin, G., Zietman, Stone, N., ... Klotz, L. (2000). Combined androgen deprivation with radiotherapy for prostate cancer: Does it make sense? Molecular Urology, 4(3), 209-213+215.

Combined androgen deprivation with radiotherapy for prostate cancer : Does it make sense? / Garzotto, Mark; D'Amico, A.; Bruchovsky, N.; Sufrin, G.; Zietman; Stone, N.; Grignon, D.; Civantos, F.; Bostwick, D.; Klotz, L.

In: Molecular Urology, Vol. 4, No. 3, 2000, p. 209-213+215.

Research output: Contribution to journalArticle

Garzotto, M, D'Amico, A, Bruchovsky, N, Sufrin, G, Zietman, Stone, N, Grignon, D, Civantos, F, Bostwick, D & Klotz, L 2000, 'Combined androgen deprivation with radiotherapy for prostate cancer: Does it make sense?', Molecular Urology, vol. 4, no. 3, pp. 209-213+215.
Garzotto M, D'Amico A, Bruchovsky N, Sufrin G, Zietman, Stone N et al. Combined androgen deprivation with radiotherapy for prostate cancer: Does it make sense? Molecular Urology. 2000;4(3):209-213+215.
Garzotto, Mark ; D'Amico, A. ; Bruchovsky, N. ; Sufrin, G. ; Zietman ; Stone, N. ; Grignon, D. ; Civantos, F. ; Bostwick, D. ; Klotz, L. / Combined androgen deprivation with radiotherapy for prostate cancer : Does it make sense?. In: Molecular Urology. 2000 ; Vol. 4, No. 3. pp. 209-213+215.
@article{203d0928f18d48a5ae2e295743e4977d,
title = "Combined androgen deprivation with radiotherapy for prostate cancer: Does it make sense?",
abstract = "Currently, our understanding of the mechanism(s) of radiation-induced death of prostate cancer is limited. In-depth analysis of these processes would facilitate the design of more effective treatment strategies utilizing radiation therapy. An increasingly recognized form of radiation-induced death is postmitotic apoptosis. In this process, radiation damages the tumor cell's DNA. The cell then divides prior to completing DNA repair, an event that is lethal. In order to avoid this fate, the cancer cell may attempt to halt its cell-cycle machinery temporarily to repair its DNA prior to dividing. In the treatment of prostate cancer, radiation therapy currently is being evaluated in combination with androgen deprivation (AD). However, because AD can induce growth arrest, it may reduce the effectiveness of radiation through a reduction in postmitotic apoptosis. To study this effect, we examined the effect of AD on prostate cancer radiosensitivity as it is related to cell-cycle progression. Androgen-sensitive prostate cancer cells demonstrated increased resistance to radiation when deprived of androgenic stimuli. Thus, paradoxically, AD may reduce the radiosensitivity of prostate cancer by means of cell-cycle delay, which results in a reduction in postmitotic apoptosis.",
author = "Mark Garzotto and A. D'Amico and N. Bruchovsky and G. Sufrin and Zietman and N. Stone and D. Grignon and F. Civantos and D. Bostwick and L. Klotz",
year = "2000",
language = "English (US)",
volume = "4",
pages = "209--213+215",
journal = "Molecular Urology",
issn = "1091-5362",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Combined androgen deprivation with radiotherapy for prostate cancer

T2 - Does it make sense?

AU - Garzotto, Mark

AU - D'Amico, A.

AU - Bruchovsky, N.

AU - Sufrin, G.

AU - Zietman,

AU - Stone, N.

AU - Grignon, D.

AU - Civantos, F.

AU - Bostwick, D.

AU - Klotz, L.

PY - 2000

Y1 - 2000

N2 - Currently, our understanding of the mechanism(s) of radiation-induced death of prostate cancer is limited. In-depth analysis of these processes would facilitate the design of more effective treatment strategies utilizing radiation therapy. An increasingly recognized form of radiation-induced death is postmitotic apoptosis. In this process, radiation damages the tumor cell's DNA. The cell then divides prior to completing DNA repair, an event that is lethal. In order to avoid this fate, the cancer cell may attempt to halt its cell-cycle machinery temporarily to repair its DNA prior to dividing. In the treatment of prostate cancer, radiation therapy currently is being evaluated in combination with androgen deprivation (AD). However, because AD can induce growth arrest, it may reduce the effectiveness of radiation through a reduction in postmitotic apoptosis. To study this effect, we examined the effect of AD on prostate cancer radiosensitivity as it is related to cell-cycle progression. Androgen-sensitive prostate cancer cells demonstrated increased resistance to radiation when deprived of androgenic stimuli. Thus, paradoxically, AD may reduce the radiosensitivity of prostate cancer by means of cell-cycle delay, which results in a reduction in postmitotic apoptosis.

AB - Currently, our understanding of the mechanism(s) of radiation-induced death of prostate cancer is limited. In-depth analysis of these processes would facilitate the design of more effective treatment strategies utilizing radiation therapy. An increasingly recognized form of radiation-induced death is postmitotic apoptosis. In this process, radiation damages the tumor cell's DNA. The cell then divides prior to completing DNA repair, an event that is lethal. In order to avoid this fate, the cancer cell may attempt to halt its cell-cycle machinery temporarily to repair its DNA prior to dividing. In the treatment of prostate cancer, radiation therapy currently is being evaluated in combination with androgen deprivation (AD). However, because AD can induce growth arrest, it may reduce the effectiveness of radiation through a reduction in postmitotic apoptosis. To study this effect, we examined the effect of AD on prostate cancer radiosensitivity as it is related to cell-cycle progression. Androgen-sensitive prostate cancer cells demonstrated increased resistance to radiation when deprived of androgenic stimuli. Thus, paradoxically, AD may reduce the radiosensitivity of prostate cancer by means of cell-cycle delay, which results in a reduction in postmitotic apoptosis.

UR - http://www.scopus.com/inward/record.url?scp=0033766249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033766249&partnerID=8YFLogxK

M3 - Article

C2 - 11062376

AN - SCOPUS:0033766249

VL - 4

SP - 209-213+215

JO - Molecular Urology

JF - Molecular Urology

SN - 1091-5362

IS - 3

ER -